Compare ACET & HERZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACET | HERZ |
|---|---|---|
| Founded | 1947 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 30.4M |
| IPO Year | 2017 | 1995 |
| Metric | ACET | HERZ |
|---|---|---|
| Price | $2.48 | $13.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $29.00 | N/A |
| AVG Volume (30 Days) | ★ 284.0K | 19.5K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.62 |
| 52 Week High | $9.97 | $19.30 |
| Indicator | ACET | HERZ |
|---|---|---|
| Relative Strength Index (RSI) | 15.77 | 29.41 |
| Support Level | N/A | N/A |
| Resistance Level | $9.51 | $16.45 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 6.57 | 7.22 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.